Protara's TARA-002 Shows 72% Complete Response Rate in NMIBC Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy TARA?
Source: Newsfilter
- Clinical Trial Results: TARA-002 demonstrates a 72% complete response rate in BCG-Naïve NMIBC patients, indicating significant potential in treating non-muscle invasive bladder cancer, which could transform existing treatment paradigms.
- Safety Profile: The trial reported no Grade 3 or higher treatment-related adverse events, showcasing TARA-002's favorable safety and tolerability, which will enhance confidence among physicians and patients regarding this therapy.
- FDA Feedback: The company received written feedback from the FDA on the registrational path for TARA-002, confirming that BCG is not required as a comparator, providing flexibility for future trial designs and potentially accelerating the approval process.
- Trial Progress: The company expects to report interim results from approximately 25 evaluable BCG-Unresponsive patients in Q1 2026 and aims to complete enrollment of this registrational cohort in the second half of 2026, demonstrating a proactive approach in advancing clinical development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TARA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TARA
Wall Street analysts forecast TARA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.530
Low
23.00
Averages
25.50
High
30.00
Current: 6.530
Low
23.00
Averages
25.50
High
30.00
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride
- Trial Initiation: Protara Therapeutics has dosed the first patient in its pivotal THRIVE-3 trial for intravenous Choline Chloride, aiming to become the first FDA-approved treatment for choline deficiency in patients reliant on long-term parenteral support, addressing a significant market gap.
- Patient Enrollment: The study plans to enroll approximately 105 patients to assess the efficacy and safety of low- and high-dose IV Choline Chloride, which is expected to significantly reduce the risks of hepatic injury and neuropsychological impairment faced by nearly 78% of long-term parenteral support patients.
- Regulatory Progress: IV Choline Chloride has received Fast Track and Orphan Drug Designation from the FDA, underscoring its potential in treating this underserved population, with interim analysis results anticipated in the second half of 2026.
- Market Performance: Protara's stock is currently trading at $5.46, reflecting a 6.42% increase from its 52-week low of $2.77, indicating positive market expectations and increased investor confidence in the new therapy.
See More
Protara Therapeutics Receives FDA Breakthrough and Fast Track Designations for TARA-002
- FDA Designation: Protara Therapeutics' TARA-002 has received both Breakthrough Therapy and Fast Track designations from the FDA, aimed at providing effective treatment for pediatric patients with lymphatic malformations, highlighting the drug's potential to address significant unmet medical needs.
- Accelerated Clinical Development: TARA-002 has been selected for the CMC Development and Readiness Pilot Program, which aims to support expedited clinical development, enabling earlier patient access to the therapy and significantly shortening the time to market.
- Market Opportunity: Lymphatic malformations are common in children, with over 50% of cases diagnosed at birth, and Protara's treatment is poised to fill a therapeutic gap in this area, addressing the growing market demand.
- Strategic Collaboration: Protara's CEO stated that the company will work closely with the FDA to define the registration pathway for TARA-002, with a meeting expected in the first half of this year to further advance the clinical application of this therapy.
See More
Protara Closes $75 Million Public Offering of 13 Million Shares
- Successful Fundraising: Protara Therapeutics has completed a public offering of 13,043,479 shares at a price of $5.75 per share, raising approximately $75 million, which strengthens its financial position to support clinical projects.
- Clear Use of Proceeds: The net proceeds from this offering will be used for the clinical development of TARA-002 and other clinical programs, demonstrating the company's strong commitment to drug development aimed at driving future business growth.
- Strong Underwriting Team: J.P. Morgan, TD Cowen, and Piper Sandler acted as joint book-running managers for the offering, enhancing market confidence in the offering and indicating the company's solid reputation in capital markets.
- Compliance Assurance: The offering was conducted under an effective S-3 registration statement, ensuring compliance and reducing legal risks, thereby laying a foundation for future fundraising activities.
See More
Protara Therapeutics Closes $75 Million Public Offering of 13 Million Shares
- Successful Fundraising: Protara Therapeutics has completed a public offering of 13,043,479 shares at $5.75 per share, raising approximately $75 million in gross proceeds, thereby enhancing its financial capacity to support clinical projects.
- Clear Use of Proceeds: The net proceeds from this offering will be directed towards the clinical development of TARA-002 and other clinical programs, demonstrating the company's ongoing commitment and strategic focus in the treatment of cancer and rare diseases.
- Strong Underwriting Team: The offering was managed by J.P. Morgan, TD Cowen, and Piper Sandler as joint book-running managers, which bolsters market confidence in Protara and enhances its brand influence.
- Regulatory Compliance Assurance: The shares were issued under an effective shelf registration statement on Form S-3, ensuring compliance and reducing future financing legal risks, further solidifying the company's position in the capital markets.
See More
Protara Secures $75 Million Funding to Support TARA-002 and Expand Pipeline Development
Stock Performance: Protara Therapeutics Inc. (TARA) shares fell over 18% to $5.55 in premarket trading following the announcement of a $75 million public offering of 13 million shares at $5.75 each.
Offering Details: The underwriters have a 30-day option to purchase an additional 1.95 million shares, with the offering expected to close around December 8, 2025, subject to customary conditions.
Use of Proceeds: The net proceeds from the offering will support the clinical development of TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, as well as other clinical initiatives and general corporate purposes.
Current Trials and Designations: TARA-002 is in a Phase 2 trial for pediatric lymphatic malformations and has received Rare Pediatric Disease and Orphan Drug designations, while Protara is also advancing IV Choline Chloride, which has similar designations from the FDA.
See More
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
- FDA Approval: ScinoPharm Taiwan (TWSE:1789) received FDA approval for its Glatiramer Acetate Injection for treating adult multiple sclerosis patients, marking the company's first finished drug approval and paving the way for regulatory submissions in Europe and Asia for broader commercialization.
- Market Reaction: Following this announcement, ScinoPharm's stock price rose by 3.08% to NT$23.40 on January 8, 2025, reflecting positive market sentiment regarding the product's prospects.
- Clinical Trial Progress: The approval supports the company's competitiveness in the global market, as Glatiramer Acetate remains a key product despite revenue erosion from generics, highlighting its ongoing relevance in the biotech sector.
- Strategic Positioning: This approval not only strengthens ScinoPharm's position in the biopharmaceutical landscape but also lays the groundwork for future market expansions, demonstrating the company's commitment to innovative drug development.
See More
Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride
- Trial Initiation: Protara Therapeutics has dosed the first patient in its pivotal THRIVE-3 trial for intravenous Choline Chloride, aiming to become the first FDA-approved treatment for choline deficiency in patients reliant on long-term parenteral support, addressing a significant market gap.
- Patient Enrollment: The study plans to enroll approximately 105 patients to assess the efficacy and safety of low- and high-dose IV Choline Chloride, which is expected to significantly reduce the risks of hepatic injury and neuropsychological impairment faced by nearly 78% of long-term parenteral support patients.
- Regulatory Progress: IV Choline Chloride has received Fast Track and Orphan Drug Designation from the FDA, underscoring its potential in treating this underserved population, with interim analysis results anticipated in the second half of 2026.
- Market Performance: Protara's stock is currently trading at $5.46, reflecting a 6.42% increase from its 52-week low of $2.77, indicating positive market expectations and increased investor confidence in the new therapy.
See More
Protara Therapeutics Receives FDA Breakthrough and Fast Track Designations for TARA-002
- FDA Designation: Protara Therapeutics' TARA-002 has received both Breakthrough Therapy and Fast Track designations from the FDA, aimed at providing effective treatment for pediatric patients with lymphatic malformations, highlighting the drug's potential to address significant unmet medical needs.
- Accelerated Clinical Development: TARA-002 has been selected for the CMC Development and Readiness Pilot Program, which aims to support expedited clinical development, enabling earlier patient access to the therapy and significantly shortening the time to market.
- Market Opportunity: Lymphatic malformations are common in children, with over 50% of cases diagnosed at birth, and Protara's treatment is poised to fill a therapeutic gap in this area, addressing the growing market demand.
- Strategic Collaboration: Protara's CEO stated that the company will work closely with the FDA to define the registration pathway for TARA-002, with a meeting expected in the first half of this year to further advance the clinical application of this therapy.
See More
Protara Closes $75 Million Public Offering of 13 Million Shares
- Successful Fundraising: Protara Therapeutics has completed a public offering of 13,043,479 shares at a price of $5.75 per share, raising approximately $75 million, which strengthens its financial position to support clinical projects.
- Clear Use of Proceeds: The net proceeds from this offering will be used for the clinical development of TARA-002 and other clinical programs, demonstrating the company's strong commitment to drug development aimed at driving future business growth.
- Strong Underwriting Team: J.P. Morgan, TD Cowen, and Piper Sandler acted as joint book-running managers for the offering, enhancing market confidence in the offering and indicating the company's solid reputation in capital markets.
- Compliance Assurance: The offering was conducted under an effective S-3 registration statement, ensuring compliance and reducing legal risks, thereby laying a foundation for future fundraising activities.
See More
Protara Therapeutics Closes $75 Million Public Offering of 13 Million Shares
- Successful Fundraising: Protara Therapeutics has completed a public offering of 13,043,479 shares at $5.75 per share, raising approximately $75 million in gross proceeds, thereby enhancing its financial capacity to support clinical projects.
- Clear Use of Proceeds: The net proceeds from this offering will be directed towards the clinical development of TARA-002 and other clinical programs, demonstrating the company's ongoing commitment and strategic focus in the treatment of cancer and rare diseases.
- Strong Underwriting Team: The offering was managed by J.P. Morgan, TD Cowen, and Piper Sandler as joint book-running managers, which bolsters market confidence in Protara and enhances its brand influence.
- Regulatory Compliance Assurance: The shares were issued under an effective shelf registration statement on Form S-3, ensuring compliance and reducing future financing legal risks, further solidifying the company's position in the capital markets.
See More
Protara Secures $75 Million Funding to Support TARA-002 and Expand Pipeline Development
Stock Performance: Protara Therapeutics Inc. (TARA) shares fell over 18% to $5.55 in premarket trading following the announcement of a $75 million public offering of 13 million shares at $5.75 each.
Offering Details: The underwriters have a 30-day option to purchase an additional 1.95 million shares, with the offering expected to close around December 8, 2025, subject to customary conditions.
Use of Proceeds: The net proceeds from the offering will support the clinical development of TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, as well as other clinical initiatives and general corporate purposes.
Current Trials and Designations: TARA-002 is in a Phase 2 trial for pediatric lymphatic malformations and has received Rare Pediatric Disease and Orphan Drug designations, while Protara is also advancing IV Choline Chloride, which has similar designations from the FDA.
See More
